SCHEMBL1396760

SCHEMBL1396760

COCCNc1cc[nH]c(=O)c1C(=O)N(c1ccccc1)c1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cn1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PTK2B Q14289 6/20 0.57
▸ PTK2 Q05397 3/20 0.57
▸ MET P08581 10/20 0.48
▸ KDR P35968 4/20 0.45
▸ AURKA O14965 1/20 0.45
▸ LCK P06239 1/20 0.45
▸ LYN P07948 1/20 0.45
▸ FLT1 P17948 1/20 0.45
▸ TEK Q02763 1/20 0.45
▸ AURKB Q96GD4 1/20 0.45
▸ IGF1R P08069 1/20 0.44
▸ PDGFRA P16234 2/20 0.44
▸ SYK P43405 1/20 0.44
▸ EIF2AK3 Q9NZJ5 1/20 0.43
▸ EIF2AK4 Q9P2K8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1396864 0.93 PTK2B (0.57) PTK2BPTK2METKDRAURKA
SCHEMBL1396814 0.90 PTK2B (0.53) PTK2BPTK2METKDRIGF1R
SCHEMBL1396791 0.89 PTK2B (0.55) PTK2BPTK2METKDRAURKA
SCHEMBL1396796 0.88 PTK2B (0.54) PTK2BPTK2METKDRPDGFRA
SCHEMBL4772866 0.85 MET (0.49) PTK2BPTK2METKDRIGF1R
SCHEMBL1396745 0.85 PTK2B (0.53) PTK2BPTK2METKDRIGF1R
SCHEMBL1396843 0.84 PTK2B (0.58) PTK2BPTK2METKDRAURKA
SCHEMBL1396744 0.80 PTK2B (0.50) PTK2BMETKDRIGF1R
SCHEMBL1396753 0.79 PTK2B (0.55) PTK2BPTK2METKDRPDGFRA
SCHEMBL1396829 0.78 PTK2B (0.52) PTK2BPTK2METKDRPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2288383-A1 COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER Amgen, Inc (US) 2011-03-02 — — EP claimed
WO-2009140549-A1 COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2009-11-19 — — WO claimed
EP-2288383-A1 COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER Amgen, Inc (US) 2011-03-02 — — EP disclosed
WO-2009140549-A1 COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2009-11-19 — — WO disclosed
EP-1881976-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS Amgen Inc., (US) 2008-01-30 — — EP disclosed
WO-2006116713-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC. (US) 2006-11-02 — — WO disclosed
Send feedback